Xencor Inc (XNCR) Stock
Key stats
- Market cap
- $3.00B
- Price / Earnings ratio
- -25.1x
- EPS (TTM)
- -$1.57
- Volume
- Loading
- 52-week high
- $40.08
- 52-week low
- $10.38
Source: third-party data provider, as of November 13, 2026
Compare with XNCR
Recent news

Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
XNCR

Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
XNCR

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
XNCR

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
XNCR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 82.30
- MACD 12/26/9
- 3.56
- EMA 9 of MACD
- 2.40
- MACD histogram
- 1.15
- SMA 50
- $26.91
- Price above SMA 50
- EMA 50
- $27.87
- Price above EMA 50
- SMA 200
- $17.85
- Price above SMA 200
- EMA 200
- $19.88
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.64 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
XNCR

Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
XNCR

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
XNCR

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
XNCR

Xencor to Present at the 2026 Cantor Global Healthcare Conference
Xencor to Present at the 2026 Cantor Global Healthcare Conference
XNCR

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
XNCR

Xencor Reports Second Quarter 2026 Financial Results
Xencor Reports Second Quarter 2026 Financial Results
XNCR

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
XNCR

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
XNCR

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
XNCR
News tone: automated (AI) classification of the article's content, not a price prediction.
About Xencor Inc
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Bassil I. Dahiyat Ph.D. | Co-Founder, CEO, President & Director | 1970 |
| Mr. Bart Jan Cornelissen | Senior VP & CFO | 1978 |
| Dr. John R. Desjarlais Ph.D. | Executive VP of Research & Chief Scientific Officer | 1964 |
| Ms. Celia E. Eckert J.D. | Senior VP, General Counsel & Corporate Secretary | 1972 |
| Mr. Charles Liles | Associate Director and Head of Corporate Communications & Investor Relations | — |
| Ms. Jennifer Sandoz | Senior VIce President of Human Resources | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 82.30
- MACD 12/26/9
- 3.56
- EMA 9 of MACD
- 2.40
- MACD histogram
- 1.15
- SMA 50
- $26.91
- Price above SMA 50
- EMA 50
- $27.87
- Price above EMA 50
- SMA 200
- $17.85
- Price above SMA 200
- EMA 200
- $19.88
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $21.00
- Average
- $41.11
- High
- $70.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.3 | +12.4 | ||||||||||
| 2022 | -17.4 | -6.5 | -13.6 | -12.5 | -14.1 | +25.6 | -0.6 | -5.8 | -4.2 | +8.4 | +5.1 | -13.5 |
| 2023 | +26.9 | -6.1 | -14.3 | -6.8 | +0.1 | -8.0 | -2.4 | -8.5 | -10.2 | -10.9 | +5.0 | +12.9 |
| 2024 | -16.9 | +20.4 | -7.1 | -4.5 | -0.7 | -21.0 | +7.4 | -12.1 | +18.7 | +7.0 | +20.4 | -14.4 |
| 2025 | -23.2 | -12.8 | -26.4 | +13.7 | -26.3 | -8.4 | +3.1 | +1.9 | +37.2 | +24.3 | +24.2 | -7.3 |
| 2026 | -19.0 | +5.5 | -2.0 | -4.8 | -6.4 | +36.4 | +31.4 | +40.6 | -10.6 | +20.4 | +34.8 |



